QIAGEN reports strong preliminary results for third quarter of 2020

QIAGEN to complement COVID-19 testing portfolio with novel kit that simplifies and accelerates PCR analysis for research applications

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

QIAGEN to launch rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen

The following press release is in German language only - QIAGEN investiert mehr als 110 Mio. Euro in die Erhöhung der Produktions-kapazitäten für Coronavirus-Tests

QIAGEN to launch easy-to-use digital test in the U.S. for rapid detection of SARS-CoV-2 antibodies following FDA emergency use authorization

QIAGEN announces new Chairman of Supervisory Board

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN expands integrated coronavirus NGS and software solutions to accelerate COVID-19 research  

QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short